Clinical trials: Islets of Langerhans Transplantation
Type 1 Diabetes, Hypoglycemia
Islet Allotransplantation With Steroid Free Immunosuppression
The restoration of endogenous insulin secretion carries significant hopes for shifting the paradigm of life long exogenous insulin therapy in selected groups of patients with type 1 diabetes(T1D).
- Conditions
- Type 1 Diabetes, Hypoglycemia, Metabolic Diseases
- Trial name
- NCT00446264
- Testing
- islet transplantation, daclizumab - sirolimus - tacrolimus
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Lille
Diabetes Mellitus, Type I
Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients
The purpose of the study is to learn if islet transplantation is an effective treatment for Type 1 diabetes in people who have had a kidney transplant.
- Trial name
- NCT00888628
- Testing
- Purified Pancreatic Islets, Etanercept
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Type 1
Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression
The primary purpose of this study is to demonstrate the safety of allogeneic islet transplantation in type 1 diabetic patients performed at the University of Illinois at Chicago (UIC).
- Trial name
- NCT00566813
- Testing
- Islet Cell Transplant, Islet Cell Transplant plus
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Illinois Chicago
Type 1 Diabetes Mellitus
Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus
SPECIFIC AIMS: To reverse hyperglycemia and insulin dependency in patients with Type 1 diabetes mellitus by islet cell transplantation.
- Trial name
- NCT00315614
- Testing
- Islet Transplantation and Bone Marrow
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Miami
Type 1 Diabetes Mellitus
Islet Transplantation for Type 1 Diabetes Mellitus
The complex program of insulin replacement for type 1 diabetes that is current clinical standard of care is difficult to implement for long periods of time, associated with an increased risk of severe hypoglycemia and implemented…
- Trial name
- NCT00437398
- Testing
- Islet Transplant
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Type 1 Diabetes Mellitus
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
In an earlier Phase 1/2 clinical trial using the Edmonton Protocol of steroid free immunosuppression, investigators at University of Illinois at Chicago (UIC) demonstrated the safety of islet preparation, iset transplantation…
- Trial name
- NCT00679042
- Testing
- Islets of Langerhans transplantation
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- CellTrans Inc.
Diabetes Mellitus, Insulin-Dependent
Islet Transplantation for Type 1 Diabetes
The purpose of this study is to test whether the islet cell transplantation procedures and results from a previous study in Edmonton, Canada, can be repeated.
- Trial name
- NCT00014911
- Testing
- Islet Transplantation, Sirolimus, Tacrolimus
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes
Pancreatic Islet Cell Transplantation
The purpose of this study is to assess a novel approach to immunosuppression in allogenic pancreatic islet cell transplant recipients.
- Trial name
- NCT00214786
- Testing
- Islet cell transplantation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Baylor Research Institute
Type 1 Diabetes
Incretin Effect and Use After Clinical Islet Transplantation
We aim to study if the administration of medications to increase the secretion of hormones from the intestines can improve glycemic control, reduce insulin use and promote β-cell regeneration/expansion in subjects with type 1…
- Trial name
- NCT00768651
- Testing
- Pantoprazole, Sitagliptin
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University of Alberta
Diabetes Mellitus, Type 1
Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression
This trial will study the ability of islet transplantation to restore glycemic control and achieve insulin independence in type 1 diabetic subjects with life-threatening hypoglycemia and unawareness, or recurrent hyperglycemia…
- Trial name
- NCT00133809
- Testing
- Transplantation of Human Islets
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Emory University
Type 1 Diabetes Mellitus, Hypoglycemia
Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes
The primary objective of this protocol is to test the safety and efficacy of a treatment regimen consisting of maintenance therapy with efalizumab and sirolimus for 1 year followed by withdrawal of efalizumab and maintenance…
- Trial name
- RAPTIVA (NCT00672204)
- Testing
- Allogeneic islets of Langerhans transplant, Raptiva, Sirolimus
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Minnesota
Pancreatectomy for Chronic Pancreatitis
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
The study is a phase 2/3, multicenter, double-blind, parallel assignment study. It involves 100 adult recipients of an intra-hepatic pancreatic Islet Auto-Transplantation (IAT).
- Trial name
- NCT01967888
- Testing
- Reparixin
- Where
- 9 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- Dompé Farmaceutici S.p.A
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
This trial is conducted in Europe and North America. The aim of this trial is to investigate if liraglutide treatment can increase the proportion of insulin-independent subjects one year after islet cell transplantation who…
- Trial name
- NCT01206101
- Testing
- liraglutide
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 3 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Severe Hypoglycemic Unawareness
A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control.
- Trial name
- NCT01897688
- Testing
- Islet Cell Transplant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Diabetes Mellitus, Type 1
Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation
The purpose of this study is to reverse hyperglycemia and insulin dependency, by islet cell transplantation, in patients with type 1 diabetes mellitus who have a stable kidney allograft.
- Trial name
- NCT00315588
- Testing
- Islet Transplantation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Rodolfo Alejandro
Chronic Pancreatitis, Insulin Dependent Diabetes
Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT
This will be a pilot, 12-month phase II, open label, randomized, two-arm, single-blinded, placebo-controlled, parallel clinical trial of individuals undergoing TPAIT (Total Pancreatectomy and Autologous Islet Transplantation) for…
- Trial name
- NCT03283566
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Cleveland Clinic
Type 1 Diabetes
Calcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet Transplantation
Our final objective is to develop an adoptive therapy with tolerogenic donor-specific Tr1 cells in T1D patients undergoing pancreatic islet transplantation (Tx).
- Trial name
- ECIT-1 (NCT01346085)
- Testing
- CNI free immunosuppression
- Where
- 2 sites in Italy, Switzerland
- Volunteers
- 10 people
- Sponsor
- Ospedale San Raffaele
Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus
Reparixin in Pancreatic Islet Transplantation
Inhibition of CXCL8 activity might represent a relevant therapeutic target to prevent injury occurring after pancreatic islet transplantation. Reparixin is a novel and specific inhibitor of CXCL8.
- Trial name
- NCT01220856
- Testing
- Reparixin
- Where
- 2 sites in Germany, Italy
- Volunteers
- 9 people
- Sponsor
- Dompé Farmaceutici S.p.A
Islet Transplantation in Diabetes Mellitus Type 1
Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation
The objective of this clinical trial was: to assess whether Reparixin leads to improved transplant outcome as measured by glycaemic control following intra-hepatic infusion of pancreatic islets in patients with Type 1 diabetes…
- Trial name
- REP0211 (NCT01817959)
- Testing
- Reparixin
- Where
- 9 sites in United States, Czechia and 3 more
- Volunteers
- 51 people
- Sponsor
- Dompé Farmaceutici S.p.A
Type 1 Diabetes Mellitus
Islet Transplantation Using Abatacept
Islet transplantation in type 1 diabetics with hypoglycemic unawareness using abatacept as a part of a novel calcineurin-inhibitor-sparing immunosuppressive regimen.
- Trial name
- NCT00276250
- Testing
- Efalizumab, Abatacept, Belatacept
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University